Piper Sandler analyst Korinne Wolfmeyer raised the firm’s price target on Hims & Hers to $35 from $24 and keeps a Neutral rating on the shares. The firm notes the company delivered solid Q4 results, but says it is remaining cautious given the high level of uncertainty that comes with 2025. Management is still anticipating meaningful contribution from weight loss despite compounded Semaglutide no longer being offered.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Optimistic Buy Rating for Hims & Hers Health Amid Strong FY25 Outlook and Diversified Weight Loss Solutions
- Hims & Hers Health Faces Growth Challenges Amid Mixed Financial Performance: Sell Rating Maintained
- Hims & Hers price target raised to $27 from $25 at Citi
- Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
- Hims & Hers Health, Inc. Reports Strong 2024 Growth